Co-stimulation

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Retrieved on: 
Monday, February 12, 2024

MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB

Key Points: 
  • MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB
    Planegg/Martinsried, February 12, 2024.
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the selection of gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma, as the initial clinical indications for its lead candidate MDG1015.
  • Preclinical data presented in 2023 at the AACR and ESMO conferences demonstrated the clear potential of MDG1015 to improve clinical outcomes in solid tumors.
  • “The selection of these cancers as targets for MDG1015 is an important step as we advance towards the first-in-human trial.

Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, October 18, 2022

DALLAS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that the first patient has been dosed in a Phase 1 dose escalation study of ITIL-306 (NCT05397093) for the treatment of multiple solid tumors. ITIL-306 is Instil’s first genetically-engineered Costimulatory Antigen Receptor-TIL (CoStAR-TIL) therapy.

Key Points: 
  • Instils first-in-human Phase 1 study of ITIL-306 is an open-label, multicenter study in patients with non-small cell lung cancer, ovarian cancer, and renal cell carcinoma.
  • ITIL-306 is an autologous TIL cell therapy engineered with a novel and proprietary CoStAR molecule that is activated by folate receptor alpha (FR) to provide robust costimulatory signals within the tumor microenvironment.
  • Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing TIL therapies for the treatment of patients with cancer.
  • Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported second quarter 2022 financial results and provided a business update.

Key Points: 
  • RTX-240 is designed to broadly stimulate the immune system by activating and expanding both NK and CD8+ memory T cells to generate an anti-tumor response.
  • Net loss for the second quarter of 2022 was $44.2 million or $0.49 per common share, compared to $50.2 million or $0.56 per common share in the second quarter of 2021.
  • In the second quarter of 2022, Rubius invested $33.0 million in research and development (R&D) related to its novel RED PLATFORM and towards expanding and advancing its product pipeline, as compared to $36.1 million in the second quarter of 2021.
  • G&A expenses were $9.9 million during the second quarter of 2022, as compared to $13.9 million for the second quarter of 2021.

Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 10, 2022

We plan to report initial clinical results from the combination arm in advanced solid tumors and initial data from the NSCLC and RCC patients in the second half of 2022.

Key Points: 
  • We plan to report initial clinical results from the combination arm in advanced solid tumors and initial data from the NSCLC and RCC patients in the second half of 2022.
  • RTX-224 expresses higher copy numbers of IL-12 on the cell surface than does RTX-321.
  • Net loss for the first quarter of 2022 was $52.4 million or $0.58 per common share, compared to $42.3 million or $0.51 per common share in the first quarter of 2021.
  • G&A expenses were $12.6 million during the first quarter of 2022, compared to $13.2 million for the first quarter of 2021.

Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company will present updated results from its single-agent Phase 1 clinical trial of RTX-240 in advanced solid tumors in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held from April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company also plans to host a webcast to discuss the results from the single-agent Phase 1 trial of RTX-240 in solid tumors and AML on April 8, 2022, at 1:15 p.m. ET, following the release of the AACR abstracts.

Key Points: 
  • Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April 12, 2022, from 9:00 a.m. 12:30 p.m.
  • The Company also plans to host a webcast to discuss the results from the single-agent Phase 1 trial of RTX-240 in solid tumors and AML on April 8, 2022, at 1:15 p.m.
  • The study will include a monotherapy dose escalation phase followed by an expansion phase in specified tumor types during the Phase 2 portion of the trial.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.

Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 10, 2022

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today provided an overview of the Company’s achievements in 2021 and outlined its objectives for 2022. Pablo J. Cagnoni, M.D., president and chief executive officer, will present these updates on Wednesday, January 12, 2022, at 8:15 a.m. EST at the virtual 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Pablo J. Cagnoni, M.D., president and chief executive officer, will present these updates on Wednesday, January 12, 2022, at 8:15 a.m. EST at the virtual 40th Annual J.P. Morgan Healthcare Conference.
  • With multiple data milestones on the horizon in 2022, we are on the cusp of potentially further validating the RED PLATFORM and benefiting an even greater number of patients.
  • RTX-240 is designed to broadly stimulate the immune system by activating and expanding both NK and CD8+ memory T cells to generate a potent anti-tumor response.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.

Shattuck Labs Announces Participation in Upcoming May Conferences

Retrieved on: 
Friday, April 30, 2021

Compounds derived from Shattuck\xe2\x80\x99s proprietary Agonist Redirected Checkpoint, ARC\xc2\xae, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.

Key Points: 
  • Compounds derived from Shattuck\xe2\x80\x99s proprietary Agonist Redirected Checkpoint, ARC\xc2\xae, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.
  • The company\xe2\x80\x99s lead wholly owned program, SL-172154 (SIRP\xce\xb1-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial.
  • A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with\xc2\xa0Takeda Pharmaceuticals.
  • Shattuck has offices in both\xc2\xa0Austin, Texas and Durham, North Carolina.

Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021

Compounds derived from Shattuck\xe2\x80\x99s proprietary Agonist Redirected Checkpoint, ARC\xc2\xae, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.

Key Points: 
  • Compounds derived from Shattuck\xe2\x80\x99s proprietary Agonist Redirected Checkpoint, ARC\xc2\xae, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.
  • The company\xe2\x80\x99s lead wholly owned program, SL-172154 (SIRP\xce\xb1-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial.
  • A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with\xc2\xa0Takeda Pharmaceuticals.
  • Shattuck has offices in both\xc2\xa0Austin, Texas and Durham, North Carolina.

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Retrieved on: 
Wednesday, April 28, 2021

CD19 is a biomarker for normal and malignant B cells, and it is a validated target for B cell cancer therapies.

Key Points: 
  • CD19 is a biomarker for normal and malignant B cells, and it is a validated target for B cell cancer therapies.
  • Via its CAR, NKX019 targets and binds to CD19 and eliminates CD19-expressing cells via a robust immune response in preclinical studies.
  • Preclinical models also demonstrate enhanced proliferation, persistence and activity of NK cells with the membrane-bound IL-15, an important cytokine for NK cell survival.
  • This receptor is fused to co-stimulatory and signaling domains, which amplify cell signaling and NK cell cytotoxicity.

Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

Retrieved on: 
Wednesday, March 10, 2021

CBL-B attenuates T-cell activation initiated by TCR engagement in part by mediating the requirement for CD28 co-stimulation, thus setting the threshold for T cell activation.

Key Points: 
  • CBL-B attenuates T-cell activation initiated by TCR engagement in part by mediating the requirement for CD28 co-stimulation, thus setting the threshold for T cell activation.
  • NX-1607 is an investigational, orally bioavailable, small molecule inhibitor of CBL-B.
  • NX-1607 treatment leads to stimulatory effects on human immune cells at low nanomolar concentrations.
  • Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.